drugset / Trial / NCT00606502
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this clinical study is to determine the effectiveness (ability to provide beneficial treatment of the disease) and safety of pralatrexate compared to erlotinib when given to non-small cell lung cancer (NSCLC) patients who are current or former cigarette smokers and who have received at least 1 prior treatment with a platinum drug (cisplatin or carboplatin)
Timeline
- Start
- 2008-01
- Primary completion
- 2010-06-24
- Completion
- 2010-06-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Pralatrexate | Other / unclassified | 230 mg/m2 | Intravenous |
| Subject | Pralatrexate | Other / unclassified | 270 mg/m2 | Intravenous |